Subsidy Information and Financing Scheme MAFLinagliptin Tablet 5 mg For patients with type 2 diabetes mellitus and chronic kidney disease stages 3b, 4 or 5
Drug Guidance for Subsidy 01/07/2022 Sitagliptin for treating type 2 diabetes mellitus The Ministry of Health’s Drug Advisory Committee has recommended: sitagliptin 25 mg, 50 mg an... See all × 01/07/2022 Sitagliptin for treating type 2 diabetes mellitus The Ministry of Health’s Drug Advisory Committee has recommended: sitagliptin 25 mg, 50 mg and 100 mg tablets in line with their registered indications for improving glycemic control in patients with type 2 diabetes mellitus, in view of acceptable price proposal from the manufacturer. Subsidy status RSitagliptin 25 mg, 50 mg and 100 mg tablets are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications. NRSDL subsidy does not apply to combination products containing sitagliptin or other DPP-4 inhibitors.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet 5 mg Alexandra Hospital Changi General Hospital Institute of Mental Health KK Women's and Children's Hospital Khoo Teck Puat Hospital National Cancer Centre National Heart Centre National Healthcare Group Polyclinics Ng Teng Fong General Hospital National University Hospital National University Polyclinics Sengkang General Hospital Singapore General Hospital SingHealth Polyclinics Tan Tock Seng Hospital Woodlands Health Campus